【摘要】 目的应用Meta分析的方法评价奥扎格雷钠联合川芎嗪注射液治疗急性脑梗死的有效性和安全性。方法计算机检索Cochrane图书馆、Pub Med、EMbase、万方数据、中国知识资源总库(CNKI)和维普期刊资源整合服务平台等,并辅以手工检索,纳入奥扎格雷钠联合川芎嗪注射液治疗急性脑梗死的随机对照试验(RCT)的相关文献,筛选文献并对纳入文献进行方法学质量评价,采用Rev Man 5.2统计软件进行Meta分析。结果共纳入15个RCT,合计1519例患者。Meta分析显示,奥扎格雷钠联合川芎嗪注射液治疗急性脑梗死的神经功能缺损临床疗效比值比(OR)合并值为4.59(95%可信区间为3.33~6.34,P<0.000 01);神经功能缺损评分疗效加权均数差(WMD)合并值为-3.80(95%可信区间为-4.10~-3.49,P<0.000 01)。结论奥扎格雷钠联合川芎嗪注射液治疗急性脑梗死临床疗效确切,未见明显不良反应。由于现有的研究质量不高,仍需要更多大样本、多中心的RCT加以验证。更多还原

【Abstract】 Objective To assess the effectiveness and safety of ozagrel sodium combined with ligustrazine injection in the treatment of acute cerebral infarction(ACI) through Meta analysis. Methods Cochrane library, Pub Med, EMbase, Wanfang Data, CNKI and VIP were under computer retrieval combined with manual retrieval. Articles about randomized controlled trails(RCTs) about ozagrel sodium combined with ligustrazine injection in the treatment of ACI were included. Articles were screened and included articles were evaluated through methodology quality. Review Manager 5.2 was used for Meta analysis. Results Totally 15 articles about RCT were included, involving 1519 patients. Results of Meta analysis showed that ozagrel sodium combined with ligustrazine injection could improve clinical efficacy of ACI neurologic impairment with [OR=4.59, 95%CI(3.33, 6.34), P<0.000 01] and [WMD=-3.80, 95%CI(-4.10,-3.49), P<0.000 01]. Conclusion Ozagrel sodium combined with Ligustrazine Injection shows definite clinical efficacy for ACI, without obvious adverse reactions. However, because of the existing low-quality research, more large-scale and multicentric RCTs are required to provide more convinced evidence.更多还原